Sign In
Buy CGEM
$16.50
-1.02 (-5.82%)
At Close: Jul 31, 2026
Cullinan Therapeutics Maps 2026 Data Catalysts for Autoimmune CLN-978, AML CLN-049 at TD Cowen Conference
02:05am, Monday, 09'th Mar 2026
Cullinan Therapeutics (NASDAQ: CGEM) executives highlighted upcoming clinical milestones for the company's two high-priority T-cell engager programs during remarks at the 46th Annual TD Cowen Healthca
Nadim Ahmed Sells 16,381 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock
04:44am, Wednesday, 25'th Feb 2026
Cullinan Therapeutics, Inc. (NASDAQ: CGEM - Get Free Report) CEO Nadim Ahmed sold 16,381 shares of the business's stock in a transaction that occurred on Friday, February 20th. The shares were sold at
Jennifer Michaelson Sells 11,742 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock
04:44am, Wednesday, 25'th Feb 2026
Cullinan Therapeutics, Inc. (NASDAQ: CGEM - Get Free Report) insider Jennifer Michaelson sold 11,742 shares of the business's stock in a transaction on Friday, February 20th. The stock was sold at an
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Tuesday, 24'th Feb 2026
CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-clas
Cullinan Therapeutics: Thesis Strengthening For This T-Cell Engager Specialist
05:39pm, Monday, 23'rd Feb 2026
Cullinan Therapeutics is rated a Buy, driven by a robust T-cell engager pipeline, savvy management, and a strong $430M+ cash position. CLN-049 (FLT3xCD3) shows ~30% CR rates in AML, with broad applica
Cullinan Therapeutics, Inc. (CGEM) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
04:05pm, Thursday, 19'th Feb 2026
Cullinan Therapeutics, Inc. (CGEM) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Consensus Recommendation of “Moderate Buy” by Brokerages
01:56am, Thursday, 19'th Feb 2026
Cullinan Therapeutics, Inc. (NASDAQ: CGEM - Get Free Report) has been given an average recommendation of "Moderate Buy" by the ten analysts that are presently covering the company, MarketBeat Ratings
Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit
07:00am, Wednesday, 18'th Feb 2026
CAMBRIDGE, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-clas
Cullinan Therapeutics Tees Up Catalyst-Heavy 2026 With Q2 CLN-978 Data and AML Fast Track Momentum
02:08am, Friday, 13'th Feb 2026
Cullinan Therapeutics (NASDAQ: CGEM) expects 2026 to be a catalyst-heavy year across its pipeline, led by two "high-priority" T-cell engager programs in autoimmune disease and acute myeloid leukemia (
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026
07:00am, Thursday, 05'th Feb 2026
CAMBRIDGE, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-clas
Cullinan Therapeutics: Cash-Rich Biotech With Multiple Value Drivers
11:03pm, Wednesday, 28'th Jan 2026
Cullinan Therapeutics is a cash-rich clinical-stage biotech with great autoimmune and AML T-cell research, which has promising catalysts for 2026. CGEM also partnered for zipalertinib, which is nearin
Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones
07:00am, Thursday, 08'th Jan 2026
Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data Company to complete monotherapy expansion cohorts to determine recommend
Cullinan Therapeutics (NASDAQ:CGEM) Trading 3.9% Higher – What’s Next?
05:08am, Friday, 02'nd Jan 2026
Shares of Cullinan Therapeutics, Inc. (NASDAQ: CGEM - Get Free Report) shot up 3.9% during trading on Wednesday. The stock traded as high as $10.22 and last traded at $10.31. 419,488 shares traded han
Cullinan Therapeutics (NASDAQ:CGEM) versus Precision BioSciences (NASDAQ:DTIL) Critical Analysis
01:12am, Monday, 29'th Dec 2025
Cullinan Therapeutics (NASDAQ: CGEM - Get Free Report) and Precision BioSciences (NASDAQ: DTIL - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare t
Assenagon Asset Management S.A. Has $1.05 Million Stake in Cullinan Therapeutics, Inc. $CGEM
03:20am, Thursday, 25'th Dec 2025
Assenagon Asset Management S.A. raised its stake in shares of Cullinan Therapeutics, Inc. (NASDAQ: CGEM) by 1,665.9% in the third quarter, according to its most recent 13F filing with the Securities a
